Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.58 |
| ▸ | HTR2C | P28335 | 19/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055888 | 1.00 | HTR2A (0.58) | HTR2AHTR2CHRH3 | |
| SCHEMBL29572718 | 0.96 | HTR2A (0.57) | HTR2AHTR2CHRH3 | |
| SCHEMBL5061550 | 0.96 | HTR2A (0.57) | HTR2AHTR2CHRH3 | |
| SCHEMBL29573176 | 0.93 | HTR2A (0.66) | HTR2AHTR2CHRH3 | |
| SCHEMBL5056331 | 0.93 | HTR2A (0.66) | HTR2AHTR2CHRH3 | |
| SCHEMBL14137379 | 0.93 | HTR2A (0.54) | HTR2AHTR2CHRH3 | |
| SCHEMBL5053122 | 0.92 | HTR2A (0.55) | HTR2AHTR2C | |
| SCHEMBL29572841 | 0.92 | HTR2A (0.55) | HTR2AHTR2C | |
| SCHEMBL29573393 | 0.92 | HTR2A (0.67) | HTR2AHTR2C | |
| SCHEMBL5055865 | 0.92 | HTR2A (0.67) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4119141-A1 | NELOTANSERIN FOR THE PROPHYLAXIS AND TREATMENT OF REM SLEEP BEHAVIOR DISORDER | Axovant Sciences GmbH (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | AXOVANT SCIENCES GMBH (CH) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 4/4885HRH3 40/4885 |
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | HTR2A 2/4885HTR2C 3/4885HRH3 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.